Literature DB >> 34018260

Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).

Loïc Renaud1,2, Jean Baptiste Bossard1, Benjamin Carpentier1,3, Louis Terriou1, Nathalie Cambier1,4, Guillaume Chanteau1,4, Guillaume Escure1, Remi Tilmont1, Sarah Barbieux5, Mathieu Wemeau1,6, Julia Hieulle1,6, Eileen M Boyle7, Franck Morschhauser1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34018260     DOI： 10.1111/ejh.13667

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  4 in total

Review 1.  SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma.

Authors:  Jillian Simard; Mark Roschewski
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2022-06-06

2.  Successful eradication of central nervous system infiltration of primary plasma cell leukemia by temozolomide.

Authors:  Yingying Zhai; Jingjing Shang; Weiqin Yao; Depei Wu; Chengcheng Fu; Lingzhi Yan
Journal:  Ann Hematol       Date:  2022-08-15       Impact factor: 4.030

Review 3.  Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies.

Authors:  Victor Orellana-Noia; Aseala Abousaud
Journal:  Curr Treat Options Oncol       Date:  2022-09-21

4.  Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series.

Authors:  Chuanwei Yang; Yong Cui; Xiaohui Ren; Ming Li; Kefu Yu; Shaoping Shen; Haihui Jiang; Mingxiao Li; Xiaokang Zhang; Xuzhe Zhao; Qinghui Zhu; Song Lin
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.